, with a mean AE SD value of 30.0AE12.9 ng/mL. Mean age was 54.3AE17.2 years, and most were female (77.1%) and white (87.6%). There were 723 deaths after a median follow-up of 4.8 years (interquartile range, 3.4-6.2 years). Unadjusted all-cause mortality hazard ratios (HRs) and 95% CIs for 25(OH)D values of less than 12, 12 to 19, and more than 50 ng/mL were 2.6 (95% CI, 2.0-3.2), 1.3 (95% CI, 1.0-1.6), and 1.0 (95% CI, 0.72-1.5), respectively, compared with the reference value of 20 to 50 ng/mL. In a multivariate model, the interaction between the effect of 25(OH)D and race/ethnicity on mortality was significant (P<.001). In white patients, adjusted HRs for 25(OH)D values of less than 12, 12 to 19, 20 to 50, and greater than 50 ng/mL were 2.5 (95% CI, 2.2-2.9), 1.4 (95% CI, 1.2-1.6), 1.0 (referent), and 1.0 (95% CI, 0.81-1.3), respectively. In patients of other race/ethnicity, adjusted HRs were 1.9 (95% CI, 1.5-2.3), 1.7 (95% CI, 1.1-2.6), 1.5 (95% CI, 1.0-2.0), and 2.1 (95% CI, 0.77-5.5). Conclusion: White patients with 25(OH)D values of less than 20 ng/mL had greater all-cause mortality than those with values of 20 to 50 ng/mL, and white patients had greater mortality associated with low 25(OH)D values than patients of other race/ethnicity. Values of 25(OH)D greater than 50 ng/mL were not associated with all-cause mortality. More recent debate has surfaced regarding the effect of high 25(OH)D levels on mortality. A handful of studies have reported a reverse J-shaped association between serum 25(OH)D and mortality with increased risk of all-cause mortality 4, 11, 12 and cardiovascular disease mortality 4 at 25(OH)D values greater than 50 to 60 ng/mL. We previously described an increasing incidence of 25(OH)D values greater than 50 ng/mL, which raises potential concern for the long-term impact of this change.
V itamin D deficiency is a globally prevalent condition that is associated with multiple adverse health outcomes including mortality. [1] [2] [3] An inverse relationship between serum 25-hydroxyvitamin D (25 [OH]D), the accepted measure of vitamin D status, and all-cause mortality has been reported for 25(OH)D values up to 20 to 36 ng/mL (to convert to nmol/L, multiply by 2.496). [4] [5] [6] [7] [8] [9] Higher cardiovascular, cancer, and respiratory mortality have been associated with low vitamin D status. 7, 10 More recent debate has surfaced regarding the effect of high 25(OH)D levels on mortality. A handful of studies have reported a reverse J-shaped association between serum 25(OH)D and mortality with increased risk of all-cause mortality 4, 11, 12 and cardiovascular disease mortality 4 at 25(OH)D values greater than 50 to 60 ng/mL. We previously described an increasing incidence of 25(OH)D values greater than 50 ng/mL, which raises potential concern for the long-term impact of this change. 13 Taking a cautious approach to the literature, the Institute of Medicine committee formulating Dietary Reference Intakes for vitamin D recommended a tolerable upper intake level of 4000 IU, corresponding to a serum 25(OH)D concentration of approximately 50 ng/mL. 14 The committee noted that individual vitamin D requirements Most previous studies of vitamin D and mortality have been limited by low numbers of patients with high serum 25(OH)D values, lack of racial diversity, or lack of information on cause-specific mortality or were not population-based. Our objective was to conduct a population-based study in the United States of the relationship between vitamin D status and all-cause and causespecific mortality. We hypothesized that we would observe a reverse J-shaped association between 25(OH)D concentrations and mortality.
PATIENTS AND METHODS

Olmsted County and the Rochester Epidemiology Project
Data from the Rochester Epidemiology Project (REP) were used to retrieve the cohort and outcomes data. The REP database is a rare example of a population-based medical records linkage system that includes over 50 years of health care utilization and diagnostic and laboratory data from virtually all medical care providers within Olmsted County, Minnesota, covering 98% of all health care services provided for Olmsted County residents. 15, 16 The county is served by 2 large integrated health systems, Mayo Clinic and Olmsted Medical Center, including primary through tertiary services and outpatient and hospital care. 17 More than 95% of the Olmsted County population has granted the medical records research authorization required by Minnesota law, thus allowing their records to be used for research. 18 We collected data on age at medical visit, sex, race/ethnicity, and Charlson comorbidity index score. Cause-specific mortality was assessed according to 4 International Classification of Diseases, Tenth Revision (ICD-10) subsets: circulatory system diseases (includes cardiovascular, cerebrovascular, and other vascular causes), I00-I99; respiratory diseases (includes respiratory infections and chronic respiratory diseases), J00-J98; all malignant cancers, C00-C97; and all other causes. 25 (OH)D measurement. All 2-way interactions between main effects were examined. Ties in event and censoring times were handled using the Efron method. The functional form of continuous variables was assessed using martingale residuals, and the proportional hazards assumption was assessed via plots of the Schoenfeld residuals. 20 Additionally, after examining a penalized spline fit to the martingale residuals, an outcomebased cut point analysis 21 with a logrankebased test 22 was used to look for the best initial 25(OH)D value separating 25(OH)D values into the most homogeneous groups with respect to survival. After looking at all-cause mortality, we performed similar analyses looking at the cause-specific deaths: cancer-related deaths, circulatory-related deaths, respiratory-related deaths, and other deaths (determined on the basis of the diagnosis listed first on the death certificate; circulatory ICD-10, I00-I99; respiratory ICD-10, J00-J98; cancer ICD-10, C00-C97; other, all remaining deaths). (Table 2 ). There were no significant interactions of sex and age with 25(OH)D values and mortality.
Laboratory Methods
RESULTS
The final model for all-cause mortality included age (quadratic), sex, Charlson comorbidity index score, index month, race/ethnicity, vitamin D categories, and the interaction between race/ethnicity and serum 25(OH)D (Table 3) . As in the univariate analysis, we observed a greater risk of death in males, in those who were older, and in those with a higher Charlson index score. For low 25(OH) D levels, whites were at a much higher risk of death than patients of other race/ethnicity (Figure) .
The final models for cause-specific mortality included age, sex, Charlson comorbidity index score, index month, race/ethnicity, and 25(OH) D categories (Supplemental Table 2 , available online at http://www.mayoclinicproceedings.org). The risk of cancer-related death was greater in those who were older and in those with a higher Charlson score. Low 25(OH)D values were associated with a significantly greater risk of with higher Charlson score. Those with 25(OH)D values greater than 50 ng/mL were at marginally greater risk of respiratory-related death compared with the reference category (HR, 1.95; 95% CI, 1.004-3.78; P¼.05). The risk of other causes of death was greater in those who were older, males, and with higher Charlson score. Very low 25(OH) D values of less than 12 ng/mL were associated with a significantly greater risk of other causes of death compared with the reference category of 20 to 50 ng/mL (HR, 2.72; 95% CI, 1.91-3.89; P<.001).
DISCUSSION
We found a strong association between 25(OH) D concentrations of less than 20 ng/mL and allcause mortality. There was a significant interaction by race/ethnicity, with no association for patients of other race/ethnicity even at very low 25(OH)D values (<12 ng/mL). Values of 25(OH)D greater than 50 ng/mL were not associated with greater all-cause mortality.
We confirmed the association between low 25(OH)D levels and higher all-cause mortality that has been found in previous studies, including several meta-analyses. [5] [6] [7] 10, 23 Previous studies have reported inverse relationships between serum 25(OH)D concentrations as high as 20 to 36 ng/mL and mortality. 4, 5, 23 We also found that the association between all-cause mortality and 25(OH)D values of at least 20 to 25 ng/mL was no longer statistically significant, which was in agreement with our a priori cutoff of 20 ng/mL. Lower 25(OH)D values may not cause increasing mortality but may be associated with illness and a prognostic marker for mortality. 24 However, the effects of vitamin D and its metabolites on inflammation, cellular proliferation, genetic regulation, calcium homeostasis, and immune modulation could have a salutary effect in a variety of diseases that contribute to mortality. 10, 25 Low 25(OH)D values have an adverse effect on mortality independent of parathyroid hormone levels, 26 and high parathyroid hormone concentrations are associated with increased mortality independent of 25(OH)D values. 27 It is not clear that changing the 25(OH)D concentration would alter the mortality risk. Randomized trials have found a modest mortality benefit with vitamin D supplementation, although most of the included studies were not designed to evaluate mortality as a primary outcome, and most participants were white. 28 Values of 25(OH)D greater than 50 ng/mL were not associated with higher all-cause mortality. Although most previous studies found no increase in all-cause mortality associated with 25(OH)D values higher than 50 ng/ mL, 6, 23, 25 a few found an increased risk with 25(OH)D concentrations greater than 50 to 60 ng/mL. 4, 11, 12 However, vitamin D assay standardization appears to abolish the apparent increased mortality risk associated with high 25(OH)D concentrations because the radioimmunoassay used in the National Health and Nutrition Examination Survey (NHANES) III tends to inflate values of 25(OH)D greater than 40 ng/mL. 29 Most individuals with 25(OH)D values higher than 50 ng/mL are taking vitamin D to achieve these levels. Some of these patients are possibly being treated with vitamin D because they have had or are at risk for vitamin D deficiency. 30 Individuals with a disease associated with vitamin D deficiency (eg, osteoporosis) may take vitamin D even in the absence of documented vitamin D deficiency. Thus, the reported increase in all-cause mortality is likely confounded by the indication for vitamin D intake. Given the rapid increase in the incidence of 25(OH)D values greater than 50 ng/mL in the population, 13 our finding is reassuring that all-cause mortality was not increased in this group.
A novel finding of our study was the significant interaction of race/ethnicity and serum 25(OH)D in the relationship with all-cause mortality. Despite a strong association between 25(OH)D concentrations of less than 20 ng/mL and all-cause mortality in whites, this relationship was absent in patients of other race/ ethnicity, even at very low 25(OH)D values. Most previous studies involved predominantly white populations of European descent with minimal inclusion of other races/ethnicities. Of studies that adjusted for race/ ethnicity, 8, 11, 26, [31] [32] [33] [34] an interaction between the effect of race/ethnicity and 25(OH)D on all-cause mortality was not described. Allcause mortality data from the NHANES-III included an oversampling of participants whose race/ethnicity was other than white, and in a subgroup analysis, investigators reported a nonsignificant interaction by race/ethnicity. 9 In a 15-year follow-up of the same study, nonHispanic whites had an increased all-cause mortality in all 25(OH)D categories of less than 30 ng/mL, whereas non-Hispanic blacks only had increased mortality with 25(OH)D values lower than 8 ng/mL when compared with a 25(OH)D reference category of 30 to 39 ng/mL. 11 The biological and clinical implications of the race/ethnicity interaction in our study are unclear. Individuals who are not white generally have lower 25(OH)D concentrations than whites, 35, 36 an effect that is accentuated by greater latitude from the equator. 37 However, the association of low 25 41, 42 Investigators using NHANES-III data found that 25(OH)D concentrations of less than 15 ng/mL were associated with higher fatal stroke compared with concentrations of 15 ng/mL or higher in whites but not in blacks after adjusting for multiple covariates. 43 Others using the NHANES-III data found that the excess cardiovascular mortality seen in blacks was completely eliminated after adjusting for 25(OH)D levels and income. 44 The strengths of our study include a large community-based population and access to comprehensive data from primary through tertiary care for nearly the entire population. All measurements of 25(OH)D were performed in the same laboratory with isotope-dilution liquid chromatographyetandem mass spectrometry, which provides optimal accuracy of 25(OH)D values, and no standardization adjustment was necessary.
However, our study had limitations that are worth noting. We do not have a true population sample, and women are overrepresented. This issue may be related to more frequent measurement of 25(OH)D in women, who are at greater risk of osteoporosis than men. Study participants were those who presented for care and had 25(OH)D measured, so some selection bias is likely. Our population is less ethnically diverse than the US population, which may limit generalizability; in particular, among our population of patients of other race/ethnicity, only 75 individuals died (Supplemental Table 1 
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